A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
Completed
Glaxo Wellcome
Phase 2
1969-12-31
To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis
agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP)
in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and
SMX/TMP in AIDS patients with an acute episode of PCP.
Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine
isetionate. Although both treatments are equally effective, side effects prevent completion
of therapy in 11-55 percent of patients.
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
1969-12-31
To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis
agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP)
in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and
SMX/TMP in AIDS patients with an acute episode of PCP.
Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine
isetionate. Although both treatments are equally effective, side effects prevent completion
of therapy in 11-55 percent of patients.
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Completed
National Cancer Institute (NCI)
Phase 2
1993-06-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
patients with AIDS-related lymphoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
